Suchergebnisse - "Dreyling, Martin"

PubPharm (566)

11

Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma

enthalten in: Leukemia & lymphoma | 2024

von Hess, G. | Dreyling, M. | Oberic, L. | +22

12

Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimus

enthalten in: Hematological oncology | 2023

von Moosburner, M. | Alibegovic, L. | Hasselmann, K. | +7

13

Principles of oncology taught in a one-week course

enthalten in: Journal of cancer research and clinical oncology | 2023

von Oettle, M. | Büttner, M. | Forster, M. | +12

14

The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL

enthalten in: American journal of hematology | 2023

von Rejeski, K. | Wang, Y. | Albanyan, O. | +17

15

PTCY-Based Haploidentical Donor Transplantation versus HLA-Matched Related and Unrelated Donor Transplantations in Patients with Refractory or Relapsed Lymphoma-A Matched-Pair Analysis

enthalten in: Cancers | 2023

von Haebe, S. | Fraccaroli, A. | Stauffer, E. | +7

16

Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features : a phase 1/2 trial of the European MCL network (SAKK 36/13)

enthalten in: EClinicalMedicine | 2023

von Novak, U. | Fehr, M. | Schär, S. | +21

17

Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease forms

enthalten in: Leukemia | 2023

von Kalmbach, S. | Grau, M. | Zapukhlyak, M. | +26

18

The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma-a pooled trials analysis

enthalten in: Annals of hematology | 2023

von Fischer, L. | Jiang, L. | Bittenbring, J. | +15

19

Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)

enthalten in: Leukemia | 2023

von Scheubeck, G. | Jiang, L. | Hermine, O. | +11

20

Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe : The SCHOLAR-2 retrospective chart review study

enthalten in: British journal of haematology | 2023

von Hess, G. | Dreyling, M. | Oberic, L. | +22